.svg)
et's get the tired myth out of the way first: porn performers are not dirty. They are, statistically speaking, among the most frequently and rigorously tested sexually active people on the planet. The adult industry has operated its own standardized testing infrastructure for years through PASS (the Performer Availability Screening Services system) which requires talent to test every 14 days for a battery of STIs before they are cleared to work on set. No test, no shoot, and that is not a suggestion. It is the protocol, and the industry enforces it with more consistency than most public health guidelines could dream of demanding from the general population.
So the next time someone implies that adult performers are walking petri dishes, consider this: that person probably last got tested when their doctor remembered to ask, which is not the same thing as every two weeks with results verified before anyone touches anyone. The random you met at a bar last Saturday has almost certainly not been screened for anything recently. Your favorite performer has been screened, cleared, and documented. The math on who is actually cleaner is not particularly close.
None of which makes performers immune to STIs, because nothing does. Bacterial infections in particular (chlamydia and gonorrhea chief among them) show up on testing panels with enough regularity to constitute a genuine operational problem for the industry. A positive result triggers an automatic 14-day hold off set, mandatory treatment, and a contact tracing process that ripples through everyone on recent call sheets. It is disruptive for the performer, disruptive for the production, and it is a health risk that no amount of protocol can fully eliminate because, as of right now, there is no vaccine for either infection.
Why Gonorrhea and Chlamydia Have Been So Hard to Vaccinate Against
The short answer is that bacterial vaccines are significantly harder to develop than viral ones, and the pharmaceutical industry has historically not prioritized infections that are treatable with antibiotics. Why pour billions into a vaccine when a course of doxycycline does the job? The answer to that question, which is becoming increasingly urgent, is antimicrobial resistance. Gonorrhea in particular has developed resistance to nearly every antibiotic class that has been thrown at it over the decades. The treatment options that remain are narrowing, and the window for catching this problem before it becomes catastrophic is not wide.
That is the backdrop against which Eli Lilly announced last week that it is acquiring Swiss biotech LimmaTech Biologics for up to $780 million. LimmaTech has been quietly developing vaccines against bacterial pathogens for years, and its pipeline includes early-stage candidates for both Neisseria gonorrhoeae (the bacteria that causes gonorrhea) and Chlamydia trachomatis (the bacteria that causes chlamydia). The company's lead program, LTB-SA7, targets Staphylococcus aureus and is already in Phase 1 human trials. The gonorrhea and chlamydia programs sit behind it in preclinical development, which is further along than anything else credible in this space.
What makes LimmaTech's approach technically interesting is that it does not target bacterial surface antigens, the conventional strategy that tends to fail because bacteria mutate their surface proteins to evade immune responses. Instead, LimmaTech's technology targets the toxins and superantigens that bacteria use to cause damage in the body. The immune response that produces is designed to be broader and more durable — better suited to organisms that are actively evolving to resist our tools.
What Lilly's Money Actually Changes
LimmaTech was a promising small biotech with candidates it could not realistically get through Phase III clinical trials on its own balance sheet. That is the fate of a significant percentage of early-stage drug development: good science, insufficient capital, program stalls. Lilly's acquisition changes that equation. Eli Lilly is the company currently printing money on its obesity drugs Mounjaro and Zepbound, and it has been deploying that capital into acquisitions at a pace that signals genuine strategic intent. The LimmaTech deal was one of three infectious disease acquisitions Lilly announced simultaneously on May 26th, part of nearly $3.83 billion in deals announced in a single day. This is not a company making speculative bets with spare change. It is a company buying its way into a prevention strategy it intends to see through.
Lilly's chief scientific officer Daniel Skovronsky said in the announcement that as antimicrobial resistance continues to erode treatment options, vaccines are increasingly the only viable path to prevention. He specifically named infertility as one of the long-term consequences the company is targeting. That detail matters in this context: chlamydia is the leading preventable cause of infertility in women, and performers who cycle through repeated infections over the course of a career carry that cumulative risk in a way that most people quietly dating around do not.
The Honest Caveat
Preclinical means preclinical. The gonorrhea and chlamydia vaccine candidates have not entered human trials yet, and the road from where they are to regulatory approval is realistically measured in years, not months. Pharmaceutical development at this stage does not guarantee a finished product — plenty of promising candidates have not survived the transition from animal models to humans. What has changed is not the science itself but the resources behind it, and in drug development those are not the same thing. Under a small biotech's constraints, these programs might stall or be deprioritized indefinitely. Under Lilly, they have a plausible path forward.
For an industry that has spent decades building some of the most rigorous sexual health testing infrastructure in existence, the addition of effective bacterial STI vaccines to that toolkit would be a meaningful shift. The 14-day holds, the contact tracing, the operational disruption of a positive panel — none of that goes away overnight, and it will not go away even with a vaccine for some time yet. But the science is finally moving in the right direction, with serious money behind it, and that is more than could have been said before last week.
The adult industry has always taken sexual health more seriously than the culture that stigmatizes it. It would be a particular kind of justice if the vaccines that eventually close the gap on bacterial STIs end up benefiting everyone, including the people who spent the last twenty years pretending performers were the problem.
This article draws on original reporting by Austin King for PornCrush.
